

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0128

TITLE: Metabolizing Enzyme Polymorphisms and Prognosis Among  
Women Treated for Breast Cancer

PRINCIPAL INVESTIGATOR: Carol Sweeney, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota  
Minneapolis, Minnesota 55455-2070

REPORT DATE: October 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030313 151

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

**1. AGENCY USE ONLY (Leave blank)****2. REPORT DATE**

October 2002

**3. REPORT TYPE AND DATES COVERED**

Annual (28 Sep 01 - 27 Sep 02)

**4. TITLE AND SUBTITLE**Metabolizing Enzyme Polymorphisms and Prognosis Among  
Women Treated for Breast Cancer**5. FUNDING NUMBERS**

DAMD17-01-1-0128

**6. AUTHOR(S)**

Carol Sweeney, Ph.D.

**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**University of Minnesota  
Minneapolis, Minnesota 55455-2070

E-Mail: sweeney@epi.umn.edu

**8. PERFORMING ORGANIZATION  
REPORT NUMBER****9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING  
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited.

**12b. DISTRIBUTION CODE****13. ABSTRACT (Maximum 200 Words)**

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. During the first year of funding, we have completed compilation of tumor registry data for eligible subjects (Task 1 of the approved statement of work). We have also completed study start-up tasks, including IRB review, hiring study staff, creating data collection forms, establishing a study database, and training study staff on data collection procedures. Collection of tissue samples (Task 2 of the approved statement of work) has begun. Activities currently in progress include obtaining pathology slides and blocks, review of slides by the study pathologist, and abstracting information from pathology reports into the study database. As described in the statement of work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 1.

**14. SUBJECT TERMS**

Breast cancer, GSTP1, GSTA1, DNA

**15. NUMBER OF PAGES**

6

**16. PRICE CODE****17. SECURITY CLASSIFICATION  
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION  
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION  
OF ABSTRACT**

Unclassified

**20. LIMITATION OF ABSTRACT**

Unlimited

## Table of Contents

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>5</b>
<b>Key Research Accomplishments.....</b>	<b>6</b>
<b>Reportable Outcomes.....</b>	<b>6</b>
<b>Conclusions.....</b>	<b>6</b>
<b>References.....</b>	<b>6</b>
<b>Appendices.....</b>	<b>6</b>

## INTRODUCTION

Despite the favorable prognosis for women treated for breast cancer, in some instances cancer will recur. Host factors may explain some differences in outcomes of treatment. Variability in enzyme activities could be a factor influencing sensitivity of cells to cancer treatment. Common polymorphisms occur in several genes encoding drug metabolizing enzymes, and the variant alleles affect enzyme activities. Glutathione *S*-transferase (GST) A1 and GSTP1 enzymes catalyze inactivating glutathionyl conjugation reactions of chemotherapeutics including cyclophosphamide. The GSTA1\*B variant reduces expression of GSTA1, while a GSTP1 Val<sup>105</sup> variant reduces specific activity toward alkylating agents, so these polymorphisms may improve treatment effect by reducing removal of the drug. Data from a pilot study indicate that among women treated for breast cancer, those who are homozygous for GSTP1 Val<sup>105</sup> or GSTA1\*B have improved overall survival. In the present study we will investigate whether presence of inherited variant alleles affecting activity of metabolizing enzymes affect overall survival or time to recurrence outcomes, and whether these associations are independent of other prognostic factors. The study will be a retrospective study of women (n=700) receiving first course of therapy for invasive, primary breast cancer, identified through a hospital tumor registry. Information on vital status and recurrence will be obtained from registry follow-up data. We will determine genotypes using DNA extracted from normal tissue from archived surgical blocks. We will assess other prognostic markers in tumor tissue by immunohistochemistry. We will use survival analysis methods, taking into account other prognostic factors, to evaluate associations between genotypes and recurrence and overall survival.

## BODY

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes.

The Statement of Work identified five tasks, as follows:

*Task 1.* Compilation of Data for Eligible Subjects, Months 1-3

*Task 2.* Archived Tissue Specimens Obtained, Months 4-24

*Task 3.* DNA Extraction and Genotyping, Months 6-30

*Task 4.* Immunohistochemistry, Months 6-30

*Task 5.* Data Analysis and Report Writing, Months 18-36

During the first year of funding, we have completed Task 1, compilation of tumor registry data for eligible subjects. We have also completed the following study start-up activities: IRB review and approval; hiring study staff; creating data collection forms for pathology report abstraction and pathological review of each case for eligibility; establishing a database for entering abstracted, unidentified data and tracking specimen status; training study staff on data collection procedures. Task 2, collection of tissue samples, is underway. Activities a. through f. specified under Task 2 are currently in progress including obtaining pathology slides and blocks, review of slides by the study pathologist, and abstracting information from pathology reports into the study database. Samples are being prepared to carry out laboratory assays, Tasks 3 and 4, during years 2 and 3.

## KEY RESEARCH ACCOMPLISHMENTS

Data collection activities have been initiated and are proceeding. As described in the Statement of Work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 1. The PI presented a poster describing study methods and rationale at the "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, Florida, September 26-28, 2002.

## REPORTABLE OUTCOMES

### Abstract

Sweeney C, Gulbahce HE, Coles BF. Metabolizing enzyme polymorphisms and prognosis among women treated for breast cancer. "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, September 26-28, 2002.

## CONCLUSIONS

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. Data collection activities have been initiated and are proceeding. As described in the Statement of Work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 1.

## REFERENCES

N/A

## APPENDICES

N/A